These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 3098500)

  • 1. Small-pool high-yield factor VIII production.
    Smit Sibinga CT
    Crit Rev Clin Lab Sci; 1986; 24(1):43-70. PubMed ID: 3098500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.
    Smit Sibinga CT; Daenen SM; van Imhoff GW; Maas A; Das PC
    Thromb Haemost; 1984 Feb; 51(1):12-5. PubMed ID: 6426077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
    Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
    Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in large-scale purification of factor VIII/von Willebrand factor concentrates using ion-exchange chromatography.
    Mori F; Nardini I; Rossi P; Nardini C; Farina C
    Vox Sang; 2008 Nov; 95(4):298-307. PubMed ID: 19138259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing factor VIII activity in frozen plasma.
    Swärd-Nilsson AM; Persson PO; Johnson U; Lethagen S
    Vox Sang; 2006 Jan; 90(1):33-9. PubMed ID: 16359353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet collection during plasma exchange donation of cryoprecipitate.
    McLeod BC; Sassetti RJ; Cole ER; Scott JP
    Prog Clin Biol Res; 1990; 337():481-3. PubMed ID: 2112755
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of a peptidomimetic ligand for efficient isolation and purification of factor VIII via affinity chromatography.
    Knör S; Khrenov AV; Laufer B; Saenko EL; Hauser CA; Kessler H
    J Med Chem; 2007 Sep; 50(18):4329-39. PubMed ID: 17691762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An improved thaw-siphon method for the cryoprecipitate preparation.
    Kang EP
    Vox Sang; 1980; 38(3):172-7. PubMed ID: 6770544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased yield of F VIII from pooled plasma vs. single-donor plasma in the production of cryoprecipitates.
    Rácz Z; Thék M; Jánossy A; Pintér J; Baróti C
    Arch Med Res; 1997; 28(2):179-82. PubMed ID: 9204605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII.
    McLeod BC; Scott JP
    Prog Clin Biol Res; 1990; 324():189-98. PubMed ID: 2106687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F VIII subunits: purification and antigenic properties.
    Nordfang O; Ezban M; Hansen JJ
    Thromb Haemost; 1987 Dec; 58(4):1043-8. PubMed ID: 3127917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Storage of whole blood for up to 24 hours at ambient temperature before component preparation: implementation in the Netherlands.
    Pietersz RN
    Transfusion; 2011 Jan; 51 Suppl 1():3S-6S. PubMed ID: 21223289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possibilities to elevate the factor VIII yield].
    Uteg KH; Tausendfreund K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(1):153-69. PubMed ID: 2439416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma.
    Konecka G; Bykowska K; Ludwicka A; Letowska M; Wegrzynowicz Z; Sablinski J; Lopaciuk S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):565-70. PubMed ID: 1714861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of plasma with high levels of ionised calcium in the production of model scale coagulation factor concentrates.
    Farrugia A; Douglas S; James J; Whyte G; Herrington R
    Thromb Haemost; 1990 Nov; 64(3):374-8. PubMed ID: 2128967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood.
    Runkel S; Haubelt H; Hitzler W; Hellstern P
    Transfusion; 2005 Mar; 45(3):427-32. PubMed ID: 15752162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.